Lund, Sweden — 30 March 2023 — Camurus (CAMX) today announces that the Annual Report for 2022 now is available at the company’s website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF).
“2022 was a year of significant success for Camurus as we strengthened our leading position in the treatment field of opioid dependence, increased Buvidal® market share and for the first time reported full-year profit. An updated marketing authorization application for Brixadi™ was submitted to the US Food and Drug Administration (FDA), and important progress was made in our ongoing pivotal CAM2029 studies for the treatment of acromegaly, neuroendocrine tumors (NETs), and polycystic liver disease (PLD).”, says Fredrik Tiberg, President and CEO of Camurus.
The Annual Report also includes Camurus’ sustainability report.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
This information is information that Camurus AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 10:00am CET on 30 March 2023.